Fluoxetine and norfluoxetine plasma concentrations in major depression: A multicenter study

American Journal of Psychiatry

Volumn 154, Issue 7, 1997, Pages 963-969

  Amsterdam, Jay D ^a   Fawcett, Jan ^b   Quitkin, Frederic M ^b   Reimherr, Frederick W ^b   Rosenbaum, Jerrold F ^b   Michelson, David ^b   Hornig Rohan, Mady ^b   Beasley, Charles M ^b  

^a The Science Center Philadelphia   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

FLUOXETINE; NORFLUOXETINE;

ADULT; ARTICLE; DEPRESSION; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; HAMILTON SCALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RATING SCALE; REMISSION; RISK ASSESSMENT; RISK FACTOR; TREATMENT PLANNING;

EID: 0031006298     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.154.7.963     Document Type: Article

References (30)

1. Amsterdam J, Brunswick D, Mendels J: Clinical application of tricyclic antidepressant pharmacokinetics and plasma levels. Am J Psychiatry 1980; 137:653-662
2. Kupfer DJ, Hanin I, Spiker EG: Amitriptyline plasma concentrations and clinical response in primary depression. Clin Pharmacol Ther 1977; 22:904-911
3. Glassman AH, Perel JM, Shostak M, Kantor SJ, Fleiss JL: Clinical implications of imipramine plasma concentrations for depressive illness. Arch Gen Psychiatry 1977; 34:197-204
4. Asberg M, Cronholm B, Sjoqvist F, Tuck D: Relationship between plasma level and therapeutic effect of nortriptyline. BMJ 1971; 3:331-334
5. Whyte SF, MacDonald S, Ghose K: Plasma concentrations of protripryline and clinical effects in depressed women. Br J Psychiatry 1976; 128:384-390
6. Amsterdam JD, Brunswick DJ, Potter L, Winokur A, Rickels K: Desipramine and 2-hydroxydesipramine plasma levels in endogenous depressed patients: lack of correlation with a therapeutic response. Arch Gen Psychiatry 1985; 42:361-364
7. Mendlewicz J, Linkowski P, Rees JA: Double-blind comparison of doxepin and amitriptyline in patients with primary affective disorder: serum concentrations and clinical response. Br J Psychiatry 1980; 136:154-160
8. Amsterdam J, Brunswick DJ, Mendels J: High dose desipramme, plasma drug levels and clinical response. J Clin Psychiatry 1979; 40:141-143
9. Simpson GM, Sing H: Tricyclic antidepressants, in Pharmacotherapy of Depression: Application for Outpatient Practitioners. Edited by Amsterdam J. New York, Marcel Dekker, 1990, pp 75-110
10. Wernicke JF, Bosomworth JC, Ashbrook E: Fluoxetine at 20 mg per day: the recommended and therapeutic dose in the treatment of depression. Int Clin Psychopharmacol 1989; 4(suppl 1):63-67
11. Schweizer E, Rickels K, Amsterdam JD, Fox I, Puzzuoli G, Weise C: What constitutes an adequate antidepressant trial of fluoxetine? J Clin Psychiatry 1990; 51:8-11
12. Fava M, Rosenbaum JF, Cohen L, Reiter S, McCarthy M, Stengar R, Clancy K: High-dose fluoxetine in the treatment of depressed patients not responsive to a standard dose of fluoxetine. J Affect Disord 1992; 25:229-234
13. Fava M, Rosenbaum JF, McGrath PJ, Stewart JW, Amsterdam JD, Quitkin FM: Lithium and tricyclic augmentation of fluoxetine treatment for resistant major depression: a double-blind, controlled study. Am J Psychiatry 1994; 151:1372-1374
14. Fava M, Rappe SM, Pava JA, Nierenberg AA, Alpert JE, Rosenbaum JF: Relapse in patients on long-term fluoxetine treatment: response to increased fluoxetine dose. J Clin Psychiatry 1995; 56:52-55
15. Kelly MW, Perry PJ, Holstad SG, Garvey MJ: Serum fluoxetine and norfluoxetine concentrations and antidepressant response. Ther Drug Monit 1989; 11:165-170
16. Beasley CM Jr, Bosomworth JC, Wernicke JF: Fluoxetine: relationships among dose response, adverse events, and plasma concentrations in the treatment of depression. Psychopharmacol Bull 1990; 26:18-21
17. Norman TR, Gupta RK, Burrows GD, Parker G, Judd FK: Relationship between antidepressant response and plasma concentrations of fluoxetine and norfluoxetine. Int Clin Pharmacol 1993; 8:25-29
18. Perez Sola V, Perez Blanco J, Alvarez E, Queralto JM: [Plasmatic concentrations of fluoxetine, pharmacokinetics, therapeutic response and side effects]. Actas Luso Esp Neurol Psiquiatr Cienc Afines 1993; 21:143-147 (Spanish)
19. Montgomery SA, Baldwin D, Shah A, Green M, Fineberg M, Montgomery D: Plasma concentration response relationships with fluoxetine and zimelidine. Clin Neuropharmacol 1990; 13 (suppl 1):S71-S75
20. Fichtner CG, Jobe TH, Braun BG: Possible therapeutic window for serotonin reuptake inhibitors. J Clin Psychiatry 1992; 55:36-38
21. Cain JW: Poor response to fluoxetine: underlying depression, serotonergic overstimulation, or a "therapeutic window"? J Clin Psychiatry 1992; 53:272-277
22. Keck PE, McElroy SL: Ratio of plasma fluoxetine to norfluoxetine concentrations and associated sedation. J Clin Psychiatry 1992; 53:127-129
23. Spitzer RL, Williams JBW, Gibbon M, First MB: Instruction Manual for the Structured Clinical Interview for DSM-III-R (SCID). New York, New York State Psychiatric Institute, Biometrics Research, 1988
24. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
25. Nash JF, Boop RJ, Carmichael RH, Farid KZ, Lemberger L: Determination of fluoxetine and norfluoxetine in plasma by gas chromatography with electron-capture detection. Clin Chem 1982; 28:2100-2102
26. Conover WJ, Inman RL: Rank transformation as a bridge between parametric and nonparametric statistics. Am Statistician 1981; 124-132
27. Quitkin FK, Rabkin J, Markowitz J, Stewart J, McGrath P, Harrison W: Use of pattern analysis to identify true drug response. Arch Gen Psychiatry 1987; 44:259-269
28. SAS User's Guide: Statistics, version 6. Cary, NC, SAS Institute, 1990
29. Altamura AC, Moro AR, Percundani M: Clinical Pharmacokinetics of fluoxetine. Clin Pharmacokinet 1994; 26:201-214
30. Ereschefsky L, Tran-Johnson T, David CM, LeRoy A: Pharmacokinetic factors affecting antidepressant drug clearance and clinical effect: evaluation of doxepin and imipramine - new data and review. Clin Chem 1988; 34:863-880